Endogenous and exogenous sex steroid hormones have multiple effects on lipid and lipoprotein metabolism. It is also known that estrogen has antiatherogenic actions, therefore we considered examining whether there was any association between polymorphisms in estrogen-metabolizing genes and lipid levels in women. We investigated the association between variants in genes related to estrogen biosynthesis (CYP19-TTTA n ) and estrogen catabolism (CYP1A1*2A, CYP1A1*2C, CYP1A2-Asn516Asn, CYP3A4*1B, and COMT-Val158Met) with serum lipid levels in a cross-sectional study with 472 Brazilian women of European descent. They were divided into three subgroups according to their hormonal status: premenopausal women (n ¼ 187), postmenopausal women exposed to hormonal replacement therapy (HRT) (n ¼ 118), and postmenopausal women unexposed to HRT (n ¼ 167). The postmenopausal women receiving HRT who were carriers of the CYP3A4*1B variant showed lower low-density lipoprotein cholesterol levels than wild-type homozygotes. Premenopausal women homozygous for the CYP1A1*2C allele had higher high-density lipoprotein cholesterol levels than heterozygotes. While the CYP1A1*2C variant probably has a higher catalytic activity, the functional implications of the CYP3A4 polymorphism are still uncertain. These data are the first attempt to associate estrogen metabolism genes to lipid levels in women.
INTRODUCTION
The oral estrogen/hormone replacement therapy (ERT/HRT) in postmenopausal women decreases serum total cholesterol (T-chol) and low-density lipoprotein cholesterol (LDL-C) concentrations, as well as increases serum high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels. 1 However, the effects of ERT/HRT may be variable according to metabolic individuality of women; 2, 3 thus, it is important to identify factors, such as genetic variability, that may alter estrogen concentrations. Genetic polymorphisms play a critical role in determining variation in the expression of several enzymes involved in estrogen metabolism.
estrogens. 5 Aromatase is the product of the CYP19 gene, which is a member of the cytochrome P450 (CYP450) superfamily of genes. It has a tetranucleotide repeat polymorphism (TTTA) n ¼ 7À13 in intron 4 and a 3 bp deletion 50 bp upstream of the repeat. This deletion is found in those with seven repeats, generating two alleles: seven repeats with the 3 bp deletion [7r(À3)] and seven repeats without the deletion (7r). 6, 7 The tetranucleotide repeat polymorphism in intron 4 is mapped about 80 bp downstream of exon 4. 6, 7 The different genetic variants may lead to alternate splicing patterns and mRNA transcripts, which could ultimately result in a protein with modified activity. Although no data exist on the functionality of either CYP19 polymorphism, they have been associated with estrogen concentrations. 8 The phase I or estrogen oxidative catabolism is mediated by CYP450 enzymes, which catalyze NADPH-dependent monooxygenation of this hormone to yield more polar derivatives. 9 The principal CYP isoforms responsible for hepatic metabolism of 17b-estradiol (E 2 ) and estrone (E 1 ) are the CYP1A2 and CYP3A4, which are mainly involved in estrogen 2-and 4-hydroxylations; the CYP1A1 catalyzes estrogen 2-, 15a-, 5a-, and 4-hydroxylations principally in extra-hepatic tissues. 10 Catechol estrogens (2-hydroxyestradiol/E 1 and 4-hydroxyestradiol/E 1 ) are major metabolites of estrogens in humans, and their inactivation is catalyzed by catechol-O-methyltransferase (COMT), a conjugating enzyme of phase II. 11 It is possible that individual variations in metabolic activities in each phase or in the coordination of these two phases regulate the clearance of estrogens. 12 Thus, in pharmacogenetic studies, genotyping of polymorphic alleles encoding drug-metabolizing enzymes can be useful for identification of drug metabolism phenotypes. 4 Several polymorphisms have been described in the CYP1A1 gene. Two single nucleotide polymorphisms (SNPs) have been extensively studied, one in the 3 0 -non-coding region, 3801T4C denominated CYP1A1*2A according to the recommended nomenclature for the genetic polymorphisms in human P450 genes 13, 14 and the other within exon 7, CYP1A1*2C. 15 These polymorphisms are genetically linked and provide at least three-fold increases in the gene's catalytic activity. 16 The CYP3A family and CYP1A2 are the major forms of CYP450 enzymes in the human liver, accounting for approximately 30 and 13% of total CYP protein content, respectively. 17 The CYP3A4*1B variant is an A4G alteration that occurs in the nifedipine-specific element, in the 5 0 regulatory region of the CYP3A4 gene. 18 The effect of the CYP3A4*1B allele on CYP3A4 activity remains controversial. Clinical studies have postulated that the CYP3A4*1B variant results in decreased enzymatic activity; microsomal studies could not confirm an effect of this variant on enzymatic function, whereas a higher CYP3A4 expression of the CYP3A4*1B allele was reported in vitro. 19 A C4T change in the 295 position of the CYP1A2 gene (rs2470890) was described 20 ; this variant is a silent mutation in codon 516 (Asn516Asn). The functional implication of this variant has not been investigated. In humans, the COMT protein exists as two length variants, soluble (S-COMT) and membranebound (MB-COMT), 21 which are encoded by a single gene localized to chromosome 22q11.1-2. 22 A single base pair change (G4A) in exon 4 of the COMT gene, in the position 472 in the long mRNA, and in the 322 in the short mRNA, results in an amino-acid change (Val4Met), in codon 158 of MB-COMT and in codon 108 of S-COMT, that decreases the activity level of the COMT enzyme 3-4-fold. 23 Among the genes involved in estrogen metabolism, some may have an interesting potential to evaluate the clinical response to HRT because they (1) are responsible for the last estrogen biosynthesis step (CYP19), (2) have high catalytic activity in the liver for the formation of less active metabolites (CYP1A2 and CYP3A4), (3) have high catalytic activity in extra-hepatic tissues for the formation of more active metabolites (CYP1A1), or (4) are responsible by conjugation of catechol estrogens (COMT). Nevertheless, these genes have never been investigated in relation to serum lipid levels in women. Therefore, the purpose of this study was to access the possible association of polymorphic variation in these genes in women with different hormonal status on lipid and lipoprotein levels.
RESULTS
The genotype frequencies observed for all studied polymorphisms did not reveal statistically significant differences compared to those expected under Hardy-Weinberg equilibrium. The allele frequencies for all genes in the studied women are presented in Table 1 .
The women were divided into three groups according to CYP19 genotypes: 24 I-combinations of the shortest alleles Estrogen-metabolizing gene polymorphisms and lipid levels S Almeida et al (7(À3)/7(À3); 7(À3)/7; 7(À3)/8; 7/7; 7/8; 8/8; 8/9; 8/10); II-combinations of the shortest and longest alleles (7(À3)/ 11; 7(À3)/12; 7(À3)/13; 7/11; 7/12; 7/13; 8/11); and IIIcombinations of the longest alleles (11/11; 11/12; 11/13). The combination I of CYP19 polymorphism and CYP1A2*T allele was associated with higher HDL-C levels in HRT þ and HRTÀ postmenopausal women, respectively, but after multiple testing, correction P-values did not remain statistically significant (Table 2) . Premenopausal women homozygous for the CYP1A1*2C allele had higher HDL-C levels than heterozygotes (1.4670.28 and 1.1470.25 mmol/l, respectively; P ¼ 0.004); this effect was still detected after multiple testing correction (pC ¼ 0.024; Table 2 ). This genotype was not observed in postmenopausal women, and therefore its effect on HRT users was not tested.
For the CYP3A4 gene polymorphism, the statistical analyses were performed only in homozygotes for the wild-type allele and heterozygotes for the variant allele, because only four homozygotes for this variant were detected in all samples. Only the postmenopausal women HRT þ carriers of the CYP3A4*1B variant showed lower LDL-C levels than wild-type homozygotes (2.8170.37 and 3.4070.79 mmol/l, respectively; P ¼ 0.0005); this association remained significant after correction for multiple testing (pC ¼ 0.003; Table 3 ).
No significant effect was detected for CYP1A1*2A and Val158Met (COMT) polymorphisms on lipid levels in the three groups of women (data not shown).
DISCUSSION
The allele and genotype frequencies observed for the C4T polymorphism in CYP1A2 and the Val158Met polymorphism in the COMT gene were similar to those reported in other European or European-derived populations.
25, 26 The allele frequencies of the CYP1A1*2A, CYP1A1*2C, and CYP3A4*1B variants were similar to those previously described for the Brazilian population of European descent 4, 27, 28 and slightly higher than those observed in European populations. 4, 29, 30 The frequencies of the CYP19 tetranucleotide polymorphism were quite similar to those previously detected in another sample from the same population described herein. 31 The effect of ERT/HRT on lipid levels or atherosclerosis progression in women may differ according to genotypes of estrogen receptor genes (ESR1 and ESR2). [32] [33] [34] Since estrogen does have an antiatherogenic action, associations between Values in mmol/l. HRT+, postmenopausal women on hormonal replacement therapy; HRTÀ, postmenopausal women HRT nonusers; pC, corrected P.
Estrogen-metabolizing gene polymorphisms and lipid levels S Almeida et al the effect of ERT/HRT on lipid levels and genetic variations in genes involved in estrogen metabolism are expected, because the products of these genes regulate estrogen concentrations. Although it is known that several of the P450 enzymes are responsible for critical steps in the conversion of E 1 to estradiol and its subsequent catabolism, to the best of our knowledge this is the first study to investigate the association between CYP19, CYP1A1, CYP1A2, CYP3A4, and COMT polymorphisms with circulating lipid levels in women exposed and unexposed to endogenous or exogenous estrogen. Two well-studied polymorphisms genetically linked in the CYP1A1 gene, CYP1A1*2A and CYP1A1*2C, provide at least three-fold increases in its catalytic activity. 16 Estrogens are quickly metabolized, and therefore estrogen levels decrease and estrogen metabolite levels increase in carriers of the CYP1A1*2C variant. The higher HDL-C levels in premenopausal women homozygous for the variant CYP1A1*2C were an unexpected finding, because the correlation between HDL-C levels and estrogens is positive, but it may be explained by one of the estrogen metabolites to CYP1A1 hydroxylation, the 4-hydroxyestradiol/E 1 , that retains potent hormonal activity and a higher association rate with estrogen receptor than estradiol. 10, 35 It is known that the CYP3A family accounts for approximately 30% of the total hepatic CYP content. 17 Levels of CYP3A4 are approximately 4-to 14-fold higher than those of CYP1A2. This abundance defines CYP3A4 as the major CYP isoform responsible for the hepatic metabolism of estrogens. 9, 17 The present results demonstrated an effect of the CYP3A4*1B variant only in exogenous estrogen presence. We hypothesize that some differences in exogenous estrogen molecules might confer modifications in metabolism when compared to endogenous estrogens. Bennink 36 reported that ethinyl estradiol is more potent than estradiol, because the ethinyl substitution in the C17 position inhibits the first-pass hepatic metabolism.
There were some limitations to our study. It might have been exposed to selection bias and factors such as population stratification, socioeconomic status, and/or health care, which may act in different ways in HRT users and nonusers. In addition, the CYP1A2 and CYP3A4 activity can be influenced by a number of factors including body size, tobacco smoke, coffee intake, cruciferous vegetables, and some medications. 37 The observed associations might be spurious (type I error) due to multiple statistical comparisons, but we performed the Benjamini and Hochberg False Discovery Rate procedure for multiple testing corrections. However, when the probability of the type I error (false positive) decreases, the probability of the type II error (false negative) increases. The appropriate application of the multiple testing corrections is not always clear 38 and therefore the two P-values (before and after corrections) are shown. Although the possibility of statistical error could not be excluded, this work may be considered as exploratory and suggest candidate polymorphisms for association with lipid levels and for HRT pharmacogenetics studies.
The results reported represent an initial effort to understand the genetic determinants of lipid levels in women in the presence of endogenous or exogenous estrogens. Although the lipoprotein levels are only intermediate biomarkers for cardiovascular disease, our results suggest that the CYP3A4*1B and CYP1A1*2C genotypes may modulate estrogen effects on cardiovascular risk in women. This information may help elucidate pathways through which variations in these genes may influence coronary heart disease in postmenopausal women. Prospective follow-up investigations are clearly needed to elucidate if and how these polymorphisms affect safety and efficacy of HRT and if there is a subset of women that would benefit more from TRH to prevent cardiovascular disease. Since the data presented here are the first attempt to associate estrogen metabolism genes to lipid levels, replications of the present findings in larger samples are warranted.
METHODS

Study Subjects
The sample consisted of 472 Brazilian women of European descent. These women went to two clinical centers at the Universidade Federal do Rio Grande do Sul for routine blood tests or a gynecological clinical visit. In this cross-sectional study, women were divided into three subgroups according to hormonal status. The sample characteristics and demographic variables were described elsewhere. 32 Briefly, in the sample considered, 187 were premenopausal women (mean age ¼ 3479.7 years, 18-50 years), 118 were postmenopausal women receiving oral HRT with estrogen or estrogen plus progestagen (0.625 mg of conjugated equine estrogen, n ¼ 24; 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate, n ¼ 62; 2 mg of estradiol plus noretisterone acetate, n ¼ 32) for at least 4 months (HRT users-mean age ¼ 5676.7 years, range 39-75 years), and 167 were postmenopausal women who were not receiving any HRT (HRT nonusers-mean age ¼ 5879.8 years, range 38-85 years) for at least 1 year. The women were considered postmenopausal if they had no vaginal bleeding for at least 12 months without other obvious pathological or physiological cause or bilateral oophorectomy. The premenopausal women had regular menstrual bleeding within the previous 3 months. Information about health and lifestyle factors (physical activity, smoking status, alcohol consumption and hormonal contraceptives, or drugs intake) was obtained from each individual by an interview. After answering the interview, women, wearing light clothes, had their body weight and height recorded and their body mass index (BMI) calculated by the ratio of weight (in kg) and height squared (in meters). Exclusion criteria were secondary hyperlipidemia due to renal, hepatic or thyroid disease, and diabetes or fasting blood glucose levels above 6.9 mmol/ l. 39 Individuals who were taking lipid-lowering medication were excluded. Informed consent to the blood samples drawn for DNA extraction to be used in studies approved by the University Ethics Committee was obtained from each subject included in the sample.
Measurements of Lipid Serum Levels
Blood samples were collected after 12 h fasting. T-chol, HDL-C, TG, and glucose levels were determined by standard methods using commercial kits. LDL-C was calculated according to the Friedewald formula. 40 
DNA Analyses
Genomic DNA was extracted from peripheral blood leukocytes by a salting-out procedure. 41 The polymerase chain reaction (PCR) for the analysis of a C4T polymorphism in the CYP1A2 gene was carried out in a total volume of 25 ml containing 0.5-1.0 mg genomic DNA, 10 pmol each of the upstream and downstream primers (CYP1A2*11F-5 0 ATC TAC GGG CTG ACC ATG AA3 0 and CYP1A2*11R-5 0 TTG AGA TGG GGT CTT GCT CT3 0 ), 200 mmol each of four dNTP, 1.5 mM of MgCl 2 , 0.5 U Taq polymerase and 2.5 ml of PCR buffer. After an initial denaturation at 941C for 5 min, followed by 35 cycles at 941C for 30 s, 551C for 30 s, 721C for 30 s, and a final extension at 721C for 5 min, the PCR products were subjected to restriction enzyme digestion at 371C for 2 h with MfeI. To visualize CYP1A2 genotypes, digestion products were run on 2% agarose gel with ethidium bromide (336, 200, and 136 bp). The SNPs CYP1A1*2A, CYP1A1*2C, CYP3A4*1B, and Val4Met variation in COMT were amplified by PCR, using the same conditions and oligonucleotide primers as previously described. [42] [43] [44] The amplification products were subsequently digested with the following restriction enzymes under conditions recommended by the manufacturer: MspI (CY-P1A1*2A), BsrDI (CYP1A1*2C), PstI (CYP3A4*1B), and Hsp92II (COMT). The genotypes were determined after electrophoresis on agarose or acrylamide gels stained with ethidium bromide, using a 100 bp ladder to score the band sizes. The TTTA n and 3 bp deletion polymorphisms in the CYP19 gene were analyzed as described by Arvanitis et al. 45 
Statistical Analyses
Allele frequencies were estimated by gene counting. The agreement of genotype frequencies with Hardy-Weinberg expectations was tested using the w 2 test. All other tests and transformations were performed with the SPSS 8.0 statistical package. These analyses were carried out separately for premenopausal, postmenopausal women HRT þ and HRTÀ. For association analyses, the lipid and lipoproteins levels were adjusted for age, BMI, and oral contraceptive usage (in premenopausal women) by multiple regression analyses. TG levels were ln-transformed to remove skewness and its geometric means are shown in the tables. Adjusted means of lipoprotein and lipid levels were compared among genotypes of the polymorphisms by one-way analysis of variance (ANOVA) or Student's t-test. When the ANOVA provided significant results, the Tukey post hoc test for multiple comparisons was used. The Benjamini and Hochberg false discovery rate procedure was performed for multiple testing corrections. 46 
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